ADTRALZA (tralokinumab) is a prescription medication used for the treatment of moderate-to-severe atopic dermatitis (AD), commonly known as eczema, in adults and adolescents who are candidates for systemic therapy. It is a human monoclonal antibody designed to specifically target and neutralize interleukin-13 (IL-13), a key cytokine involved in the inflammation and pathophysiology of atopic dermatitis. By inhibiting the action of IL-13, ADTRALZA helps to reduce the inflammatory responses and relieve the symptoms associated with atopic dermatitis, such as itchiness, redness, and skin lesions. It is administered through subcutaneous injection and is intended for patients who have not adequately responded to or are not suitable for topical prescription therapies or other systemic treatments.